Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Assets Average (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Assets Average for 6 consecutive years, with $86.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Assets Average fell 8.52% to $86.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $86.0 million, a 8.52% decrease, with the full-year FY2023 number at $97.8 million, up 0.54% from a year prior.
  • Assets Average was $86.0 million for Q3 2024 at Actinium Pharmaceuticals, down from $89.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $119.3 million in Q3 2022 to a low of $77.5 million in Q1 2022.
  • A 4-year average of $93.2 million and a median of $87.5 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 41.25% in 2022, then dropped 26.24% in 2023.
  • Actinium Pharmaceuticals' Assets Average stood at $82.4 million in 2021, then soared by 40.12% to $115.5 million in 2022, then decreased by 26.24% to $85.2 million in 2023, then increased by 0.93% to $86.0 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Assets Average are $86.0 million (Q3 2024), $89.1 million (Q2 2024), and $84.9 million (Q1 2024).